Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SL77.0499-10 (alfuzosin hydrochloride)
SL77.0499-10 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SL77.0499-10 (alfuzosin hydrochloride) | DRUG | - |
Inclusion Criteria: * suffering from LUTS related to BPH for at least 6 months; * having an IPSS \>13; * having a urinary peak flow rate 5.0 to 12.0 mL/s for a voided volume of at least 150 mL; * having a residual urine volume \< or = 200 mL.
Top 1 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Medicus Pharma Ltd | MDCX | 1 | PHASE2 | Teverelix DP |
SL77.0499-10 is being developed for benign prostatic hyperplasia, a urological condition that causes lower urinary tract symptoms in men. It is a small molecule in Phase 2 development. The clinical program has studied it in men aged 50 years and older with lower urinary tract symptoms related to benign prostatic hyperplasia.
SL77.0499-10 is being developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical program for this small molecule in benign prostatic hyperplasia. The asset is in Phase 2 development in the urology therapeutic area.
SL77.0499-10 is in Phase 2 development. It is an investigational small molecule and has not been approved for marketing. One Phase 2 trial has been completed, and there are no active trials for this asset.
SL77.0499-10 has been studied in one completed Phase 2 trial, NCT00409357, titled a dose ranging study of alfuzosin in patients with lower urinary tract symptoms related to benign prostatic hyperplasia. The trial enrolled 473 participants in Japan, was randomized and double blind, and included men aged 50 years and older.
Yes. SL77.0499-10 is also known as SL77.0499-10 (alfuzosin hydrochloride). The two names refer to the same small molecule asset being developed by Sanofi for benign prostatic hyperplasia.